Thu, Jul 24, 2014, 5:36 AM EDT - U.S. Markets open in 3 hrs 54 mins

Recent

% | $
Click the to save as a favorite.

Eli Lilly and Company Message Board

  • bluecheese4u bluecheese4u Jan 29, 2013 8:13 AM Flag

    Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance

    Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance

    INDIANAPOLIS, Jan. 29, 2013 /PRNewswire/ --
    •Fourth quarter revenue declined 1 percent driven by Zyprexa patent expiration, largely offset by growth in other products.
    •Fourth quarter earnings per share were $0.74 (reported), or $0.85 (non-GAAP).
    •Full-year 2012 revenue declined 7 percent to $22.6 billion.
    •Full-year 2012 earnings per share totaled $3.66 (reported), or $3.39 (non-GAAP).
    •2013 guidance increased by $0.07 per share to reflect the estimated benefit from the delayed enactment of the American Taxpayer Relief Act of 2012.
    •2013 earnings per share now expected to be in the range of $4.10 to $4.25 (reported), or $3.82 to $3.97 (non-GAAP).

    Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2012.

    investorDOTlillyDOTcom/releasedetailDOTcfm?ReleaseID=736234

 
LLY
64.25+0.53(+0.83%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT